Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
about
Clinical and technological transition in breast cancerThe potential for an enhanced role for MRI in radiation-therapy treatment planningSurvival after lumpectomy and mastectomy for early stage invasive breast cancerUpdate 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant RadiotherapyUpdate 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.Breast cancer: Actual methods of treatment and future trends.To clip or not to clip the breast tumor bed? A retrospective look at the geographic miss index and normal tissue index of 110 patients with breast cancer.Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survivalSimultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trial.Accelerated partial breast irradiation using multicatheter brachytherapy for select early-stage breast cancer: local control and toxicity.Radiotherapy in the management of early breast cancer.Effects of age on the detection and management of breast cancer.Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapyQuantification of the binding potential of cell-surface receptors in fresh excised specimens via dual-probe modeling of SERS nanoparticlesImpact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trialsThe implications of breast cancer molecular phenotype for radiation oncology.Margins! Margins. Margins? How Important Is Margin Status in Breast-Preserving Therapy?Intraoperative radiation therapy delivered prior to lumpectomy for early-stage breast cancer: a single institution study.Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer.Breast-conserving therapy and modified radical mastectomy for primary breast carcinoma: a matched comparative study.Multibeam inverse intensity-modulated radiotherapy (IMRT) for whole breast irradiation: a single center experience in China.Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancerAnalysis of loco-regional and distant recurrences in breast cancer after conservative surgery.The 21-gene recurrence score and locoregional recurrence in breast cancer patients.Margin index: a useful tool for the breast surgeon?Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes.DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer.Intraoperative radiation therapy as part of breast conserving therapy of early breast cancer-Results of one-year follow-up.Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features.Prognostic factors for local recurrence following breast-conserving treatment in young women.PET and PET/CT in radiation treatment planning for prostate cancer.Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy.The role of margin status and reexcision in local recurrence following breast conservation surgery.The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis.Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy.Breast cancer under age 40: a different approach.Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.Early breast cancer: diagnosis, treatment and survivorship.The importance of surgical margins in breast cancer.
P2860
Q26863300-9F2D645B-CBA3-4AAD-A3ED-C821146802BFQ27691311-A692D951-95B4-45C5-AA55-AE7E4ED549DEQ29394313-F6B492B5-1B7C-47D5-8114-3B44920CFE34Q30318610-99DB3B8B-4CFD-483F-9BDA-6EFD239CC391Q30318823-4EEF402A-652D-4A94-8A90-361AB5C1035BQ33751802-E911B178-E836-48B2-9E8B-D843207123F9Q33762557-80AAD00A-29E0-4AE8-8371-E9746027F58AQ33843726-AF1D14E6-E5E8-42B9-8B56-BE1FD9348D1EQ33933674-FF40343D-5146-413E-B30A-2ACB4996BEB3Q34000897-BB1C8D81-8F01-487A-8436-06B984B0D8E8Q34247346-4065A68A-5C2A-405E-A76F-5B745C46ED07Q34477879-F92943CE-EB9E-4964-93F4-D291C2B896D1Q35014893-5B65779F-9F5E-4191-8B16-10208D62D40FQ35123624-B5E51D9A-87F7-4C26-9948-0F421E91BD85Q35558130-EE4BC1FA-F5C8-45D8-895E-6EED3795D4CDQ35971516-1F7EC52C-CEC6-4DD0-9997-61F301A20D4DQ35976074-4C7970C4-E248-48CF-89BE-AC09F7BF56ECQ35993143-3498AA73-DAA0-4325-9BCA-83F61DEA294BQ36416628-E6352924-D2E2-454A-B07D-C913715B74F1Q36419117-1EA65C31-8AD4-48E8-9CC7-C9D0561E7F11Q36544304-59604A08-7F8B-4414-8A20-37E540B97FA2Q36682815-65E13183-A420-4429-A486-5453BE84A615Q36903995-F1FDA8F6-657F-42A5-9E11-36E7648B7E84Q36908670-B4CA72D6-D69F-4FC9-8F5C-9CAE415D7302Q36970943-0374DEDA-86F8-47C9-8AD5-2803DCC08E7FQ37153775-FFC268B6-9B9B-4368-95B5-2DC1F7ED0B03Q37301839-904D02E8-7084-42E9-BED2-71DDB87E8F55Q37392439-75D89729-A8E5-444F-9578-441568D4977EQ37657782-2E454980-0946-493B-BE61-5B5382C1A75BQ37697240-B87DB0BD-DE07-4DF3-80BF-6EB4907FA762Q37782089-6D8BEF1F-2EFE-4769-A9DE-B22CCE75ABB0Q37909361-3A0344F5-B49C-4175-9B7A-B79B7D8BB17BQ38032186-6108DE5A-A687-4FC7-B3B9-103692CB5AB4Q38107803-D164E381-86CF-4A3D-9BBF-0A4A8F85E276Q38182847-865A4C22-F6E8-4067-81CC-B2B2CA652A3CQ38190425-1E67C694-C28A-4366-BCE7-594B4CC20F74Q38386346-3F141C18-61B1-4504-893E-22D799C4DF61Q38471204-3708088C-F21B-4AC2-9FEC-7B41F6B6215FQ38566352-0586C594-A341-4273-B1B5-F41968DDF4DFQ38591049-7072852A-B9D7-44FE-B068-453B4D3D7EE9
P2860
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Impact of pathological charact ...... C boost versus no boost trial.
@ast
Impact of pathological charact ...... C boost versus no boost trial.
@en
Impact of pathological charact ...... C boost versus no boost trial.
@nl
type
label
Impact of pathological charact ...... C boost versus no boost trial.
@ast
Impact of pathological charact ...... C boost versus no boost trial.
@en
Impact of pathological charact ...... C boost versus no boost trial.
@nl
prefLabel
Impact of pathological charact ...... C boost versus no boost trial.
@ast
Impact of pathological charact ...... C boost versus no boost trial.
@en
Impact of pathological charact ...... C boost versus no boost trial.
@nl
P2093
P2860
P356
P1476
Impact of pathological charact ...... C boost versus no boost trial.
@en
P2093
Alain Fourquet
Augustinus A M Hart
Carla C Wárlám-Rodenhuis
Dominic A X Schinagl
Françoise Collin
Harry Bartelink
Heather A Jones
Henk Struikmans
Jean-Claude Horiot
Johannes L Peterse
P2860
P304
P356
10.1200/JCO.2008.21.5764
P407
P577
2009-08-31T00:00:00Z